Panbela Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OTC.Pink
Panbela Therapeutics aims to raise capital for clinical development and debt repayment through a public offering to support a Nasdaq relisting effort.
OTC.Pink
Panbela Therapeutics is undertaking a firm commitment public offering of common stock and warrants, alongside a proposed reverse stock split, to meet listing requirements for the US Equity Listings Tier II of the CBOE.
OTC.Pink
Panbela Therapeutics is registering the resale of up to 255,600 shares of its common stock by selling securityholders, while facing challenges with Nasdaq listing compliance.
OTC.Pink
S-1/A: Panbela Therapeutics Eyes $27.8 Million in Public Offering to Advance Cancer Drug Development
Panbela Therapeutics is undertaking a best efforts public offering to raise up to $27.8 million for the clinical development of its cancer treatment candidates and for general corporate purposes.
OTC.Pink
Panbela Therapeutics aims to raise capital through a public offering of common stock and warrants to fund the clinical development of its cancer treatment candidates.
OTC.Pink
Panbela Therapeutics launches a best efforts public offering of common stock and warrants to raise capital and address Nasdaq compliance issues.